[SCHEDULE 13G/A] BioMarin Pharmaceuticals Inc SEC Filing
Viking Global and affiliated funds report a 6.4% common-stock stake in BioMarin Pharmaceuticals (BMRN). Collectively the Reporting Persons beneficially own 12,288,611 shares out of 192,001,650 shares outstanding as of June 30, 2025. Ownership is shared (no reported sole voting or dispositive power); the holdings are held across several Viking entities and funds (largest positions reported: Viking Global Investors LP 12,288,611; Viking Global Performance LLC 8,208,825; Viking Global Equities Master Ltd. 8,044,650; Viking Long Fund Master Ltd. 2,856,671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115). The filing states the securities were not acquired to change or influence control of the issuer. Signatures on the amendment are dated August 14, 2025.
Viking Global e fondi affiliati segnalano una partecipazione del 6,4% nel capitale ordinario di BioMarin Pharmaceuticals (BMRN). Complessivamente i dichiarante possiedono beneficiariamente 12.288.611 azioni su 192.001.650 azioni in circolazione alla data del 30 giugno 2025. La proprietà è condivisa (nessun potere di voto o dispositivo esclusivo dichiarato); le partecipazioni sono ripartite tra più entità e fondi Viking (posizioni maggiori riportate: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). Nel deposito si afferma che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente. Le firme sull'emendamento sono datate 14 agosto 2025.
Viking Global y fondos afiliados informan una participación del 6,4% en acciones ordinarias de BioMarin Pharmaceuticals (BMRN). En conjunto, las personas que informan poseen beneficiariamente 12.288.611 acciones de 192.001.650 acciones en circulación a 30 de junio de 2025. La propiedad es compartida (no se declara poder de voto o dispositvo exclusivo); las tenencias están distribuidas entre varias entidades y fondos de Viking (posiciones principales informadas: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). El documento indica que los valores no fueron adquiridos para cambiar o influir en el control del emisor. Las firmas en la enmienda están fechadas el 14 de agosto de 2025.
바이� 글로벌 � 계열 펀드가 바이오마� 파마슈티컬스(BMRN)� 보통� 6.4% 지분을 신고했습니다. 신고인들은 2025� 6� 30� 현재 발행주식 � 192,001,650� � 12,288,611주를 실질적으� 보유하고 있습니다. 소유권은 공동으로 보유되며(단독 의결� 또는 처분권은 신고되지 않음), 보유 지분은 여러 바이� 법인 � 펀드에 분산되어 있습니다(보고� 주요 보유: Viking Global Investors LP 12,288,611�; Viking Global Performance LLC 8,208,825�; Viking Global Equities Master Ltd. 8,044,650�; Viking Long Fund Master Ltd. 2,856,671�; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115�). 제출서류에는 해당 증권� 발행인의 지배권� 변경하거나 영향력을 행사하기 위해 취득� 것이 아니라고 명시되어 있습니다. 수정서에 대� 서명일자� 2025� 8� 14일입니다.
Viking Global et des fonds affiliés déclarent une participation de 6,4 % du capital ordinaire de BioMarin Pharmaceuticals (BMRN). Collectivement, les personnes déclarante détiennent effectivement 12 288 611 actions sur 192 001 650 actions en circulation au 30 juin 2025. La détention est partagée (aucun pouvoir de vote ou de disposition exclusif déclaré) ; les avoirs sont répartis entre plusieurs entités et fonds Viking (principales positions déclarées : Viking Global Investors LP 12 288 611 ; Viking Global Performance LLC 8 208 825 ; Viking Global Equities Master Ltd. 8 044 650 ; Viking Long Fund Master Ltd. 2 856 671 ; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1 223 115). Le dépôt indique que ces titres n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur. Les signatures de l'amendement sont datées du 14 août 2025.
Viking Global und angeschlossene Fonds melden einen Stammaktienanteil von 6,4% an BioMarin Pharmaceuticals (BMRN). Zusammen besitzen die meldenden Personen wirtschaftlich 12.288.611 Aktien von insgesamt 192.001.650 ausstehenden Aktien zum 30. Juni 2025. Das Eigentum wird geteilt (kein alleiniges Stimm- oder Verfügungsrecht angegeben); die Bestände sind auf mehrere Viking-Einheiten und -Fonds verteilt (größte gemeldete Positionen: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). In der Einreichung wird angegeben, dass die Wertpapiere nicht zum Zweck des Wechsels oder der Beeinflussung der Kontrolle des Emittenten erworben wurden. Die Unterschriften der Änderung sind auf den 14. August 2025 datiert.
- Material ownership disclosed: Reporting Persons collectively report 12,288,611 shares, equal to 6.4% of outstanding common stock, improving market transparency.
- Structured disclosure across entities: The filing breaks down holdings by each Viking entity and names involved individuals, clarifying allocation of shared voting and dispositive power.
- Certification of passive intent: Reporting Persons certify the securities were not acquired to change or influence control, indicating no announced activism.
- None.
Insights
TL;DR A coordinated disclosure shows Viking-affiliated entities hold a material 6.4% stake in BioMarin, reported as shared beneficial ownership.
The filing documents that multiple Viking funds and management-affiliated individuals may be deemed beneficial owners of 12,288,611 BioMarin shares, representing 6.4% of the reported outstanding common stock (192,001,650). The ownership is recorded as shared voting and dispositive power across entities rather than sole control. The filing includes the required joint-filing agreement and a certification that the position is not intended to influence control. For investors, this is a material ownership disclosure that increases transparency about a sizable passive position but contains no statements of intent or plans that would indicate an active campaign or control attempt.
TL;DR Material passive stake disclosed; no sole voting/dispositive power and no stated intent to exert control.
The Schedule 13G/A shows Viking-affiliated reporting persons and three Executive Committee members may be deemed to beneficially own the same 12,288,611 shares. All reported holdings are identified as shared voting and shared dispositive power; each named individual reports no sole authority. The filing includes the standard certification that the shares were not acquired to change or influence issuer control. From a governance perspective, this disclosure clarifies potential influence channels but does not indicate an active governance campaign or change in board/control intentions.
Viking Global e fondi affiliati segnalano una partecipazione del 6,4% nel capitale ordinario di BioMarin Pharmaceuticals (BMRN). Complessivamente i dichiarante possiedono beneficiariamente 12.288.611 azioni su 192.001.650 azioni in circolazione alla data del 30 giugno 2025. La proprietà è condivisa (nessun potere di voto o dispositivo esclusivo dichiarato); le partecipazioni sono ripartite tra più entità e fondi Viking (posizioni maggiori riportate: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). Nel deposito si afferma che i titoli non sono stati acquisiti per modificare o influenzare il controllo dell'emittente. Le firme sull'emendamento sono datate 14 agosto 2025.
Viking Global y fondos afiliados informan una participación del 6,4% en acciones ordinarias de BioMarin Pharmaceuticals (BMRN). En conjunto, las personas que informan poseen beneficiariamente 12.288.611 acciones de 192.001.650 acciones en circulación a 30 de junio de 2025. La propiedad es compartida (no se declara poder de voto o dispositvo exclusivo); las tenencias están distribuidas entre varias entidades y fondos de Viking (posiciones principales informadas: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). El documento indica que los valores no fueron adquiridos para cambiar o influir en el control del emisor. Las firmas en la enmienda están fechadas el 14 de agosto de 2025.
바이� 글로벌 � 계열 펀드가 바이오마� 파마슈티컬스(BMRN)� 보통� 6.4% 지분을 신고했습니다. 신고인들은 2025� 6� 30� 현재 발행주식 � 192,001,650� � 12,288,611주를 실질적으� 보유하고 있습니다. 소유권은 공동으로 보유되며(단독 의결� 또는 처분권은 신고되지 않음), 보유 지분은 여러 바이� 법인 � 펀드에 분산되어 있습니다(보고� 주요 보유: Viking Global Investors LP 12,288,611�; Viking Global Performance LLC 8,208,825�; Viking Global Equities Master Ltd. 8,044,650�; Viking Long Fund Master Ltd. 2,856,671�; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115�). 제출서류에는 해당 증권� 발행인의 지배권� 변경하거나 영향력을 행사하기 위해 취득� 것이 아니라고 명시되어 있습니다. 수정서에 대� 서명일자� 2025� 8� 14일입니다.
Viking Global et des fonds affiliés déclarent une participation de 6,4 % du capital ordinaire de BioMarin Pharmaceuticals (BMRN). Collectivement, les personnes déclarante détiennent effectivement 12 288 611 actions sur 192 001 650 actions en circulation au 30 juin 2025. La détention est partagée (aucun pouvoir de vote ou de disposition exclusif déclaré) ; les avoirs sont répartis entre plusieurs entités et fonds Viking (principales positions déclarées : Viking Global Investors LP 12 288 611 ; Viking Global Performance LLC 8 208 825 ; Viking Global Equities Master Ltd. 8 044 650 ; Viking Long Fund Master Ltd. 2 856 671 ; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1 223 115). Le dépôt indique que ces titres n'ont pas été acquis dans le but de modifier ou d'influencer le contrôle de l'émetteur. Les signatures de l'amendement sont datées du 14 août 2025.
Viking Global und angeschlossene Fonds melden einen Stammaktienanteil von 6,4% an BioMarin Pharmaceuticals (BMRN). Zusammen besitzen die meldenden Personen wirtschaftlich 12.288.611 Aktien von insgesamt 192.001.650 ausstehenden Aktien zum 30. Juni 2025. Das Eigentum wird geteilt (kein alleiniges Stimm- oder Verfügungsrecht angegeben); die Bestände sind auf mehrere Viking-Einheiten und -Fonds verteilt (größte gemeldete Positionen: Viking Global Investors LP 12.288.611; Viking Global Performance LLC 8.208.825; Viking Global Equities Master Ltd. 8.044.650; Viking Long Fund Master Ltd. 2.856.671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1.223.115). In der Einreichung wird angegeben, dass die Wertpapiere nicht zum Zweck des Wechsels oder der Beeinflussung der Kontrolle des Emittenten erworben wurden. Die Unterschriften der Änderung sind auf den 14. August 2025 datiert.